In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancerInteractive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancerOutcomes data from a live webinar on applying the latest data for first-line management of HER2-positive mBC, including analyzing the latest clinical results and developing tailored interventions to address challenges with novel ADCs Program faculty:Laura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Shipra Gandhi, MD, MSAssociate ProfessorDirector, Breast Translational ResearchGlenn Family Breast CenterWinship Cancer Institute of Emory UniversityAtlanta, GeorgiaResources:To access the interactive patient cases associated with this podcast discussion, please visit the program page, to access a recording from a live webinar, and an interactive decision support tool on this topic.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related